Works matching IS 02698811 AND DT 2025 AND VI 39 AND IP 5

Results: 11

Psilocybin and ketamine affect novel neuropeptides gene expression in the rat hypothalamus.

Published in:

Journal of Psychopharmacology, 2025, v. 39, n. 5, p. 499, doi. 10.1177/02698811251330783

By:

Pałasz, Artur;
Pukowiec, Marta;
Bogus, Katarzyna;
Suszka-Świtek, Aleksandra;
Filipczyk, Łukasz;
Mordecka-Chamera, Kinga;
Worthington, John J;
Sygidus, Maria;
Wojtas, Adam;
Bysiek, Agnieszka;
Gołembiowska, Krystyna

Publication type:

Article

Pictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments.

Published in:

Journal of Psychopharmacology, 2025, v. 39, n. 5, p. 489, doi. 10.1177/02698811251330763

By:

Pouyan, Niloufar;
Aday, Jacob S;
Harte, Steven E;
Kaplan, Chelsea M;
Williams, David A;
Glynos, Nicolas G;
Herberholz, Moss;
Kruger, Daniel J;
Barron, Julie;
Mashour, George A;
Clauw, Daniel J;
Preller, Katrin H;
Schrepf, Andrew;
Boehnke, Kevin F

Publication type:

Article

The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics.

Published in:

Journal of Psychopharmacology, 2025, v. 39, n. 5, p. 474, doi. 10.1177/02698811251326937

By:

Majić, Tomislav;
Schmidt, Timo Torsten;
Gröticke, Anna;
Gasser, Peter;
Richards, William A;
Riemer, Thomas G;
Evens, Ricarda

Publication type:

Article

Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study.

Published in:

Journal of Psychopharmacology, 2025, v. 39, n. 5, p. 463, doi. 10.1177/02698811251319457

By:

Jensen, Mathias Ebbesen;
Stenbæk, Dea Siggaard;
Messell, Catharina Dragsted;
Poulsen, Emil Deleuran;
Varga, Tibor V;
Fisher, Patrick McDonald;
Nielsen, Marie Katrine Klose;
Johansen, Sys Stybe;
Volkow, Nora D;
Knudsen, Gitte Moos;
Fink-Jensen, Anders

Publication type:

Article

Catalyst for change: Psilocybin's antidepressant mechanisms—A systematic review.

Published in:

Journal of Psychopharmacology, 2025, v. 39, n. 5, p. 397, doi. 10.1177/02698811241312866

By:

Liebnau, Joshua;
Betzler, Felix;
Kerber, André

Publication type:

Article

Commentary: A framework for assessment of adverse events in psychedelic research.

Published in:

Journal of Psychopharmacology, 2025, v. 39, n. 5, p. 431, doi. 10.1177/02698811241309623

By:

Cheung, Katherine;
Ehrenkranz, Rebecca;
Hinkle, Jared T;
Yaden, David B

Publication type:

Article

Hemispheric annealing and lateralization under psychedelics (HEALS): A novel hypothesis of psychedelic action in the brain.

Published in:

Journal of Psychopharmacology, 2025, v. 39, n. 5, p. 416, doi. 10.1177/02698811241303599

By:

Levin, Adam W

Publication type:

Article

Co-use of psychedelics with other substances: Findings from the global psychedelic survey.

Published in:

Journal of Psychopharmacology, 2025, v. 39, n. 5, p. 453, doi. 10.1177/02698811241292956

By:

Lake, Stephanie;
Lucas, Philippe

Publication type:

Article

Psychedelic risks and benefits: A cross-sectional survey study.

Published in:

Journal of Psychopharmacology, 2025, v. 39, n. 5, p. 436, doi. 10.1177/02698811241292951

By:

Goldy, Sean P;
Du, Benjamin A;
Rohde, Julia S;
Nayak, Sandeep M;
Strickland, Justin C;
Ehrenkranz, Rebecca;
Levine, Michael;
Barrett, Frederick S;
Yaden, David B

Publication type:

Article

Into the wild frontier: Mapping the terrain of adverse events in psychedelic-assisted therapies.

Published in:

Journal of Psychopharmacology, 2025, v. 39, n. 5, p. 434, doi. 10.1177/02698811241292944

By:

Simonsson, Otto;
Goldberg, Simon B;
Hendricks, Peter S

Publication type:

Article

Corrigendum: Is psychedelic use associated with cancer? Interrogating a half-century-old claim using contemporary population-level data.

Published in:: 2025
Publication type:: Correction Notice